Profound Medical Corp
PROF7.340USD
-0.290-3.80%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
220.59MMarket Cap
LossP/E TTM
More Details of Profound Medical Corp Company
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Profound Medical Corp Info
Ticker SymbolPROF
Company nameProfound Medical Corp
IPO dateSep 24, 2014
CEOMenawat (Arun Swarup)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endSep 24
Address2400 Skymark Ave Unit 6
CityMISSISSAUGA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeL4W 5K5
Phone16474761350
Websitehttps://profoundmedical.com/
Ticker SymbolPROF
IPO dateSep 24, 2014
CEOMenawat (Arun Swarup)
Company Executives of Profound Medical Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Mathieu Burtnyk
Dr. Mathieu Burtnyk
President
President
43.55K
+3.53%
Ms. Murielle Lortie, CPA
Ms. Murielle Lortie, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Ellacott
Mr. Brian Ellacott
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kris Shah
Mr. Kris Shah
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Cynthia Lavoie, Ph.D.
Dr. Cynthia Lavoie, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephen Kilmer
Mr. Stephen Kilmer
Investor Relations
Investor Relations
--
--
Dr. Arun Swarup Menawat, Ph.D.
Dr. Arun Swarup Menawat, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Arthur L. Rosenthal, Ph.D.
Dr. Arthur L. Rosenthal, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rashed Dewan
Mr. Rashed Dewan
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Tom Tamberrino
Mr. Tom Tamberrino
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Mathieu Burtnyk
Dr. Mathieu Burtnyk
President
President
43.55K
+3.53%
Ms. Murielle Lortie, CPA
Ms. Murielle Lortie, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Ellacott
Mr. Brian Ellacott
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kris Shah
Mr. Kris Shah
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Cynthia Lavoie, Ph.D.
Dr. Cynthia Lavoie, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephen Kilmer
Mr. Stephen Kilmer
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
USA
1.98M
89.42%
Germany
140.00K
6.33%
Canada
94.00K
4.25%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gagnon (Neil)
11.08%
Fidelity Investments Canada ULC
6.24%
Gagnon Securities LLC
5.74%
BDC Venture Capital
4.05%
Daseke Don R
3.66%
Other
69.22%
Shareholders
Shareholders
Proportion
Gagnon (Neil)
11.08%
Fidelity Investments Canada ULC
6.24%
Gagnon Securities LLC
5.74%
BDC Venture Capital
4.05%
Daseke Don R
3.66%
Other
69.22%
Shareholder Types
Shareholders
Proportion
Individual Investor
17.76%
Investment Advisor
16.86%
Investment Advisor/Hedge Fund
10.35%
Hedge Fund
8.05%
Venture Capital
4.05%
Research Firm
0.89%
Bank and Trust
0.82%
Other
41.21%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
98
13.80M
45.71%
-1.21M
2025Q2
109
19.22M
63.94%
+1.89M
2025Q1
111
17.46M
58.11%
+331.88K
2024Q4
112
18.30M
60.96%
+5.58M
2024Q3
99
13.03M
50.47%
-205.28K
2024Q2
95
11.90M
47.64%
-1.30M
2024Q1
97
11.90M
48.14%
-1.72M
2023Q4
96
10.55M
49.23%
-617.16K
2023Q3
96
9.30M
43.52%
-5.47M
2023Q2
100
9.42M
44.37%
-6.12M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gagnon (Neil)
3.35M
11.11%
+2.82M
+531.45%
Apr 04, 2025
Fidelity Investments Canada ULC
1.89M
6.26%
+70.00K
+3.86%
Jun 30, 2025
Gagnon Securities LLC
1.75M
5.81%
+52.23K
+3.08%
Jun 30, 2025
BDC Venture Capital
1.22M
4.06%
+1.22M
--
Jul 31, 2024
Daseke Don R
1.10M
3.67%
--
--
Mar 07, 2024
Letko, Brosseau & Associates Inc.
1.20M
4%
-3.60K
-0.30%
Jun 30, 2025
Gagnon Advisors, LLC
896.67K
2.98%
--
--
Jun 30, 2025
Royce Investment Partners
764.91K
2.54%
+3.11K
+0.41%
Jun 30, 2025
Rosalind Advisors, Inc.
692.18K
2.3%
--
--
Jun 30, 2025
Menawat (Arun Swarup Ph.D.)
618.81K
2.05%
+16.67K
+2.77%
Sep 08, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Avantis International Equity ETF
0%
DFA Dimensional International Small Cap ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Avantis International Equity ETF
Proportion0%
DFA Dimensional International Small Cap ETF
Proportion0%
DFA Dimensional International Core Equity 2 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Profound Medical Corp?
The top five shareholders of Profound Medical Corp are:
Gagnon (Neil) holds 3.35M shares, accounting for 11.11% of the total shares.
Fidelity Investments Canada ULC holds 1.89M shares, accounting for 6.26% of the total shares.
Gagnon Securities LLC holds 1.75M shares, accounting for 5.81% of the total shares.
BDC Venture Capital holds 1.22M shares, accounting for 4.06% of the total shares.
Daseke Don R holds 1.10M shares, accounting for 3.67% of the total shares.
Gagnon (Neil) holds 3.35M shares, accounting for 11.11% of the total shares.
Fidelity Investments Canada ULC holds 1.89M shares, accounting for 6.26% of the total shares.
Gagnon Securities LLC holds 1.75M shares, accounting for 5.81% of the total shares.
BDC Venture Capital holds 1.22M shares, accounting for 4.06% of the total shares.
Daseke Don R holds 1.10M shares, accounting for 3.67% of the total shares.
What are the top three shareholder types of Profound Medical Corp?
The top three shareholder types of Profound Medical Corp are:
Gagnon (Neil)
Fidelity Investments Canada ULC
Gagnon Securities LLC
Gagnon (Neil)
Fidelity Investments Canada ULC
Gagnon Securities LLC
How many institutions hold shares of Profound Medical Corp (PROF)?
As of 2025Q3, 98 institutions hold shares of Profound Medical Corp, with a combined market value of approximately 13.80M, accounting for 45.71% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -18.23%.
What is the biggest source of revenue for Profound Medical Corp?
In FY2025Q2, the -- business generated the highest revenue for Profound Medical Corp, amounting to -- and accounting for --% of total revenue.
